Published in Pharmacol Biochem Behav on March 27, 2010
Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol (2012) 1.32
Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci (2011) 1.29
The endocannabinoid system in anxiety, fear memory and habituation. J Psychopharmacol (2011) 1.21
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. J Med Chem (2014) 1.05
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav (2010) 0.92
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) (2011) 0.84
Cannabinoid modulation of chronic mild stress-induced selective enhancement of trace fear conditioning in adolescent rats. J Psychopharmacol (2013) 0.81
Modulation of fear memory by dietary polyunsaturated fatty acids via cannabinoid receptors. Neuropsychopharmacology (2014) 0.79
Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys. Neuropsychopharmacology (2016) 0.78
Inhibitory signaling by CB1 receptors in smooth muscle mediated by GRK5/β-arrestin activation of ERK1/2 and Src kinase. Am J Physiol Gastrointest Liver Physiol (2014) 0.76
FAAH inhibitor OL-135 disrupts contextual, but not auditory, fear conditioning in rats. Behav Brain Res (2016) 0.75
Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 3.16
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol (1996) 1.78
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
D1 or D2 antagonism in nucleus accumbens core or dorsomedial shell suppresses lever pressing for food but leads to compensatory increases in chow consumption. Pharmacol Biochem Behav (2001) 1.50
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
Nucleus accumbens dopamine depletions make rats more sensitive to high ratio requirements but do not impair primary food reinforcement. Neuroscience (1999) 1.45
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol (2003) 1.44
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem (1999) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci (1997) 1.42
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Structure and orientation of the pore-forming peptide, melittin, in lipid bilayers. J Mol Biol (1994) 1.39
"Dead reckoning," landmark learning, and the sense of direction: a neurophysiological and computational hypothesis. J Cogn Neurosci (1991) 1.38
(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) (2001) 1.36
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol (2006) 1.32
Nucleus accumbens dopamine depletions alter relative response allocation in a T-maze cost/benefit task. Behav Brain Res (1996) 1.30
Effects of dopamine antagonists and accumbens dopamine depletions on time-constrained progressive-ratio performance. Pharmacol Biochem Behav (1998) 1.29
Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther (1999) 1.26
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol (1997) 1.25
The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology (2001) 1.24
Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol (2005) 1.22
A neurochemical and behavioral investigation of the involvement of nucleus accumbens dopamine in instrumental avoidance. Neuroscience (1993) 1.21
Lesions in medial preoptic area and bed nucleus of stria terminalis: differential effects on copulatory behavior and noncontact erection in male rats. J Neurosci (1997) 1.21
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
The role of accumbens dopamine in lever pressing and response allocation: effects of 6-OHDA injected into core and dorsomedial shell. Pharmacol Biochem Behav (1998) 1.19
Nucleus accumbens dopamine depletions in rats affect relative response allocation in a novel cost/benefit procedure. Pharmacol Biochem Behav (1994) 1.18
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol (1995) 1.17
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem (1998) 1.16
Characterization of the L lambda phase in trehalose-stabilized dry membranes by solid-state NMR and X-ray diffraction. Biochemistry (1989) 1.15
Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun (1997) 1.14
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) (2005) 1.13
Neocortical synaptogenesis, aging, and behavior: lifespan development in the motor-sensory system of the rat. Exp Neurol (1987) 1.13
Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem (1996) 1.12
Deuterium NMR investigation of ether- and ester-linked phosphatidylcholine bilayers. Biochemistry (1985) 1.12
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem (1998) 1.11
Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol (1997) 1.11
Cannabinoid CB1 antagonists and dopamine antagonists produce different effects on a task involving response allocation and effort-related choice in food-seeking behavior. Psychopharmacology (Berl) (2007) 1.11
Different effects of nucleus accumbens and ventrolateral striatal dopamine depletions on instrumental response selection in the rat. Pharmacol Biochem Behav (1993) 1.10
Nucleus accumbens dopamine depletions and time-constrained progressive ratio performance: effects of different ratio requirements. Pharmacol Biochem Behav (1999) 1.07
A microdialysis study of nucleus accumbens core and shell dopamine during operant responding in the rat. Neuroscience (1998) 1.07
Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol (1997) 1.07
Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors. Neuroscience (2010) 1.05
Forebrain circuitry involved in effort-related choice: Injections of the GABAA agonist muscimol into ventral pallidum alter response allocation in food-seeking behavior. Neuroscience (2008) 1.05
AM630 is a competitive cannabinoid receptor antagonist in the guinea pig brain. Life Sci (1997) 1.04
Pharmacological characterization of performance on a concurrent lever pressing/feeding choice procedure: effects of dopamine antagonist, cholinomimetic, sedative and stimulant drugs. Psychopharmacology (Berl) (1994) 1.03
Effects of dopamine depletions in the medial prefrontal cortex on DRL performance and motor activity in the rat. Brain Res (1994) 1.02
Sex differences in the dynamics of cue utilization and exploratory behavior. Behav Brain Res (2001) 1.02
Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim Biophys Acta (1995) 1.01
Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci (1999) 1.00
Place navigation in rats is impaired by lesions of medial septum and diagonal band but not nucleus basalis magnocellularis. Behav Brain Res (1988) 1.00
Open field locomotor effects in rats after intraventricular injections of ethanol and the ethanol metabolites acetaldehyde and acetate. Brain Res Bull (2003) 1.00
Age-related deficits on the radial maze and in fear conditioning: hippocampal processing and consolidation. Hippocampus (1998) 0.99
The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res (2004) 0.99
Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices. Neurosci Lett (1997) 0.99
Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol (2010) 0.99
Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Biol Reprod (1998) 0.98
Delta9-THC training dose as a determinant for (R)-methanandamide generalization in rats. Psychopharmacology (Berl) (1998) 0.98
Substantia nigra pars reticulata is a highly potent site of action for the behavioral effects of the D1 antagonist SCH 23390 in the rat. Psychopharmacology (Berl) (2001) 0.98
AM630 is an inverse agonist at the human cannabinoid CB1 receptor. Life Sci (1998) 0.97
A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci (1995) 0.95
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol (2009) 0.95
Effects of mild food deprivation on the estrous cycle of rats. Physiol Behav (2001) 0.95
Age-related deficits in the ability to encode contextual change: a place cell analysis. Hippocampus (2000) 0.94
Involvement of nucleus accumbens dopamine in the motor activity induced by periodic food presentation: a microdialysis and behavioral study. Brain Res (1992) 0.94
Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse (2000) 0.94
(-)-11-Hydroxy-7'-isothiocyanato-1',1'-dimethylheptyl-delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain. J Med Chem (1994) 0.93
Tremulous characteristics of the vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol Biochem Behav (1997) 0.93
Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice. Neuropharmacology (2012) 0.93
Pharmacological evaluation of iodo and nitro analogs of delta 8-THC and delta 9-THC. Pharmacol Biochem Behav (1993) 0.93
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav (2010) 0.92
Different behavioral functions of dopamine in the nucleus accumbens and ventrolateral striatum: a microdialysis and behavioral investigation. Neuroscience (1999) 0.92
Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol (1997) 0.92
Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to parkinsonian symptoms. J Neurosci (1991) 0.92